Product Description
please call me , to know more
AI Product Description
*The following content is generated by AI and is for reference only.
Rivaroxaban, marketed under the brand name Xarelto among others, is a potent oral anticoagulant belonging to the class of direct factor Xa inhibitors. Its chemical identity is defined by the molecular formula C21H24ClN5O4 and the CAS registry number 366789-28-2. This compound functions by selectively and directly inhibiting free and clot-bound factor Xa, as well as prothrombinase activity, without requiring antithrombin III for activation. By blocking this critical enzyme in the coagulation cascade, Rivaroxaban effectively prevents the conversion of prothrombin to thrombin, thereby reducing the formation of fibrin clots.
Clinically, Rivaroxaban has become a cornerstone therapy for preventing and treating venous thromboembolism (VTE). It is widely prescribed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, offering a convenient once-daily dosing regimen that often eliminates the need for routine coagulation monitoring required by traditional vitamin K antagonists like warfarin. Furthermore, it serves as a primary treatment for acute deep vein thrombosis and pulmonary embolism, followed by long-term secondary prevention. The drug is also indicated for prophylaxis against VTE following hip or knee replacement surgeries.
Due to its predictable pharmacokinetic profile and rapid onset of action, Rivaroxaban provides significant advantages over older anticoagulants, improving patient adherence and quality of life. However, like all anticoagulants, it carries a risk of bleeding complications, necessitating careful patient selection and management. While specific reversal agents such as andexanet alfa exist, clinical vigilance remains essential. As a synthetic small molecule, Rivaroxaban represents a major advancement in cardiovascular medicine, balancing efficacy with ease of use for millions of patients globally requiring effective thromboprophylaxis.